Initial experience with teriparatide in the United States

References

• US Forteo Prescribing Information: Eli Lilly and Company, Indianapolis, IN, USA, 2004
   Google Scholar
• McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. J Am Med Assoc 2002;288:2868–79
   Google Scholar
• Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safety. Toxicol Pathol 2002;30:312–21
   PubMed Web of Science ®Google Scholar
• Miller PD, Bilezikian JP, Deal C. Clinical use of teriparatide in the real world: initial insights. Endocr Pract 2004;10:139–48
   Google Scholar
• Hodsman AB, Bauer DC, Dempster D, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005;26:688–703
   PubMed Web of Science ®Google Scholar
• Data on file (FOR20060222A). Eli Lilly and Company, Indianapolis, IN, USA, 2005
   Google Scholar
• Rousculp M, Cossrow N, von Allmen H, et al. Patient utilization pattern with teriparatide: examination of a US-based retail prescription database [abstract]. Osteoporosis Int 2005;16:S82
   Google Scholar
• Data on file (FOR20060221C). Eli Lilly and Company, Indianapolis, IN, USA, 2004
   Google Scholar
• Data on file (FOR20060221A). Eli Lilly and Company, Indianapolis, IN, USA, 2005
   Google Scholar
• Data on file (FOR20060221B). Eli Lilly and Company, Indianapolis, IN, USA, 2005
   Google Scholar
• Faulkner DL, Young C, Hutchins D, et al. Patient noncompliance with hormone replacement therapy: a nationwide estimate using a large prescription claims database. Menopause 1998;5:226–9
   PubMed Web of Science ®Google Scholar
• Rozenberg S, Vandromme J, Kroll M, et al. Compliance to hormone replacement therapy. Int J Fertil Menopausal Stud 1995;40(Suppl 1):23–32
   PubMedGoogle Scholar
• Gold DT. The nonskeletal consequences of osteoporotic fractures. Psychologic and social outcomes. Rheum Dis Clin North Am 2001;27:255–62
   PubMed Web of Science ®Google Scholar
• Data on file (FOR20050519D). Eli Lilly and Company, Indianapolis, IN, USA, 2005
   Google Scholar
• Forteo (TM) [teriparatide (rDNA origin)] user manual:prefilled delivery device, 2005
   Google Scholar
• Ajayi FO, Sun H, Perry J. Adverse drug reactions: a review of relevant factors. J Clin Pharmacol 2000;40:1093–01
   Google Scholar
• Tashjian Jr AH, Chabner BA. Commentary on clinical safety of recombinant human parathyroid hormone 1–34 in the treatment of osteoporosis in men and postmenopausal women. J Bone Miner Res 2002;7:1151–61
   Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New Engl J Med 2001;344:1434–41
   PubMed Web of Science ®Google Scholar
• Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003;18:9–17
   PubMed Web of Science ®Google Scholar
• Vahle JL, Long GG, Sandusky G, et al. Bone neoplasms in F344 rats given teriparatide [rhPTH(1–34)] are dependent on duration of treatment and dose. Toxicol Pathol 2004; 32:426–8
   PubMed Web of Science ®Google Scholar
• Data on file [1691–003]. Eli Lilly and Company, Indianapolis, IN, USA, 2005
   Google Scholar
• Wiig JN, Bakken TS. Hyperparathyroidism with multiple malignant tumours of bone with giant-cells. A case report. Acta Chir Scand 1971;137:391–3
   PubMedGoogle Scholar
• Smith J, Huvos AG, Chapman M, et al. Hyperparathyroidism associated with sarcoma of bone. Skeletal Radiol 1997;26: 107–12
   PubMed Web of Science ®Google Scholar
• Betancourt M, Wirfel KL, Raymond AK, et al. Osteosarcoma of bone in a patient with primary hyperparathyroidism: a case report. J Bone Miner Res 2003;18:163–6
   PubMed Web of Science ®Google Scholar
• Bhatia A, Cannon S, Briggs T, Keen RW. Chondrosarcoma in association with primary hyperparathyroidism. J Bone Miner Res 2004;19:1200–3
   PubMed Web of Science ®Google Scholar
• Jutte PC, Rosso R, de Paolis M, et al. Osteosarcoma associated with hyperparathyroidism. Skeletal Radiol 2004;33:473–6
   PubMed Web of Science ®Google Scholar
• Bilezikian JP, Silverberg SJ. Clinical spectrum of primary hyperparathyroidism. Rev Endocr Metab Disord 2000;1:237–45
   PubMedGoogle Scholar
• Jimenez C, Yang Y, Kim HW, et al. Primary hyperparathyroidism and osteosarcoma: examination of a large cohort identifies three cases of fibroblastic osteosarcoma. J Bone Miner Res 2005;20:1562–8
   PubMed Web of Science ®Google Scholar